Market:

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive decline in lung function. On average, patients live 3 to 5 years after diagnosis. In the U.S. and Europe, approximately 200,000 people have IPF with 73,000 new cases each year. The market for pulmonary fibrosis is estimated to grow from $970 million in 2015 to $3.2 billion by 2025 as a result of an aging population, improved diagnosis, and the introduction of new therapies to the market.

Technology:

InSpira is developing novel compounds shown to inhibit and even reverse pulmonary fibrosis in our models. We believe our induced pluripotent stem cell model and other assays represent breakthrough improvements in IPF research. Until now, IPF was notoriously difficult to model and research. The standard rodent model for IPF is widely recognized as highly flawed. Historically, nearly 300 compounds that demonstrated efficacy in the bleomycin rodent model went on to fail in human clinical trials.

Advantages:

• Compounds inhibit and reverse disease progression
• Innovative research model and assays
• Enhanced understanding of biology of IPF

Development Stage:

• Advanced Prototype

Graduated in 2018